In the INSPIRE trial, 117 adults with knee osteoarthritis were randomized across four arms for six weeks: 20 g/day inulin, a digital physiotherapy supported exercise programme, both together, or a 10 g/day maltodextrin placebo.
Inulin reduced pain by roughly as much as the exercise programme did. Adjusted between group difference for pain was -1.11 (95% CI -2.18 to -0.04, p=0.045) for inulin and -1.55 (95% CI -2.52 to -0.58, p=0.002) for exercise.
The number that stands out is adherence: 3.6% dropped out of the inulin arm versus 21% from the exercise arm, p<0.01. The press release additionally reports raised butyrate and GLP-1, improved grip strength and reduced pain sensitivity in the inulin arm only; those secondary claims were not verified against the published paper.
The numbers
| Pain, inulin vs placebo | -1.11 (95% CI -2.18 to -0.04), p=0.045 |
| Pain, exercise vs control | -1.55 (95% CI -2.52 to -0.58), p=0.002 |
| Dropout, inulin vs exercise | 3.6% vs 21%, p<0.01 |
| Doses | 20 g/day inulin vs 10 g/day maltodextrin placebo |
What this does not show
- That inulin treats joint pain as well as physiotherapy. The inulin pain confidence interval runs to -0.04, essentially touching zero. An honest reading is possibly a small effect, not equivalence with exercise.
- That any of this applies to athletes. Participants were adults with knee osteoarthritis at a mean age of 67.5. The adherence finding travels reasonably well; the pain result does not travel at all.
- That 20 g/day of inulin was comfortable. Low dropout is encouraging but is not a tolerance measure, and 20 g/day sits in the range that causes bloating and gas in a meaningful minority of people.
- That the biomarker and strength results are solid. Butyrate, GLP-1, grip strength and pain sensitivity claims come from the press release, were not verified against the published abstract, and may be exploratory rather than pre specified.
- That this generalises to other fibers. Inulin is one fiber type. Adherence and tolerance findings do not automatically extend to other fibers or blends.
Caveats worth holding
- The population is adults with knee osteoarthritis at a mean age of 67, not endurance athletes.
- The inulin pain confidence interval essentially touches zero (-0.04), making the primary result fragile.
- Raised butyrate and GLP-1, improved grip strength and reduced pain sensitivity are reported only in the press release, unverified against the paper, and should be assumed exploratory until checked.
- The maltodextrin placebo at 10 g/day is a digestible carbohydrate rather than an inert control. Common and defensible, but not nothing.
- 20 g/day of inulin is a substantial dose in the range that causes bloating and gas in a meaningful minority of people; low dropout does not by itself prove comfort.
- Inulin is one fiber type; findings should not be extended to other fibers without saying so plainly.